Insiders Bet Big on These 3 Fintech and Biotech Stocks
In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only notable insider purchases recently.
Headquartered in Radnor, PA Fiscal year ends December NASDAQ: MLYS mineralystx.com
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines for hypertension and aldosterone-related adverse outcomes in comorbid conditions. These include chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its sole product candidate, lorundrostat, is an investigational, orally administered, highly selective aldosterone synthase (CYP11B2) inhibitor. It has 374-fold in vitro selectivity over cortisol synthase and an observed half-life of 10–12 hours. The company has completed six late-stage clinical trials of lorundrostat, including the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. Its NDA for uncontrolled and resistant hypertension is under FDA review, with a PDUFA target date of December 22, 2026. The company currently generates no revenue and is building a commercial infrastructure, including a sales force, medical affairs team, brand marketing and a patient support program, ahead of a potential U.S. launch. It funds operations with cash, investments and a senior secured term loan entered into in June 2026. Mineralys was founded by Catalys Pacific. Updated
In the past week or so, a fintech firm and two biotechs saw some huge insider buying. However, these were not the only notable insider purchases recently.
In the past week or so, some public offerings prompted huge insider buying. However, these were not the only notable insider purchases recently.
Though insider buying has slowed during the first-quarter earnings reporting season, some insiders continued to build stakes or bucked selling trends.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines for hypertension and aldosterone-related adverse outcomes in comorbid conditions. These include chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone.
The Wall Street consensus 12-month price target for MLYS is $43.56.